ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA® ... | May 11, 2023
Source: marketscreener.com